The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.
The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...
Our intestines are home to 100 trillion microorganisms — some beneficial ... Older adults with weakened immune systems, for example, suffer from life-threatening infections with C. difficile. Today, ...